000			02041 a2200529 4500
005			20250516184313.0
264		0	_c20140411
008			201404s 0 0 eng d
022			_a1095-6859
024	7		_a10.1016/j.ygyno.2013.11.027 _2doi
040			_aNLM _beng _cNLM
100	1		_aKorets, Sharmilee Bansal
245	0	0	_aDual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer. _h[electronic resource]
260			_bGynecologic oncology _cFeb 2014
300			_a468-73 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aCarboplatin _xadministration & dosage
650	0	4	_aCarcinoma, Endometrioid _xdrug therapy
650	0	4	_aCell Growth Processes _xdrug effects
650	0	4	_aCell Line, Tumor
650	0	4	_aEndometrial Neoplasms _xdrug therapy
650	0	4	_aEverolimus
650	0	4	_aFemale
650	0	4	_aIndoles _xpharmacology
650	0	4	_aMechanistic Target of Rapamycin Complex 1
650	0	4	_aMechanistic Target of Rapamycin Complex 2
650	0	4	_aMice
650	0	4	_aMice, Inbred BALB C
650	0	4	_aMice, Nude
650	0	4	_aMultiprotein Complexes _xantagonists & inhibitors
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors
650	0	4	_aPurines _xpharmacology
650	0	4	_aRandom Allocation
650	0	4	_aSignal Transduction
650	0	4	_aSirolimus _xadministration & dosage
650	0	4	_aTOR Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aMusa, Fernanda
700	1		_aCurtin, John
700	1		_aBlank, Stephanie V
700	1		_aSchneider, Robert J
773	0		_tGynecologic oncology _gvol. 132 _gno. 2 _gp. 468-73
856	4	0	_uhttps://doi.org/10.1016/j.ygyno.2013.11.027 _zAvailable from publisher's website
999			_c23346479 _d23346479